An increased percentage and proliferation of tumor infiltrating T lymphocytes, particularly CD8 + T cells, was also observed using this combination approach, effects which were in concordance with previous studies with other Gal-3 inhibitors (14). The gene discussed is CD8A; the disease is neoplasm.